Two hormones that sound the same but behave very differently inside the body — and the science finally explains why
When a doctor prescribes “progesterone,” they might hand you one of two very different things: a molecule that is chemically identical to what your ovaries produce, or a synthetic stand-in engineered to activate similar receptors. The terms are used interchangeably in everyday conversation — and even by some clinicians — but the distinction is increasingly recognised as clinically important.
This article untangles the science behind bioidentical (natural) progesterone and synthetic progestins, explains why they affect your tissues differently, and looks at what the latest research says about choosing one over the other.
What is progesterone, exactly?
Progesterone is a steroid hormone produced primarily by the corpus luteum after ovulation, and by the placenta during pregnancy. It’s also synthesised in small amounts by the adrenal glands and, notably, by neurons in the brain — where it plays a neuroprotective role that’s only recently been fully appreciated.
The molecule has a precise 3-D shape. It fits into progesterone receptors (PR-A and PR-B) like a key into a lock, triggering a cascade of effects that regulate the uterine lining, modulate estrogen’s proliferative signals, support the nervous system, and influence cardiovascular health.
Bioidentical simply means the molecule is structurally identical to the one your body naturally produces. When derived from plant sources (usually wild yam or soy), it’s processed in a lab to achieve that exact structure. “Natural” does not mean unprocessed — it means molecularly identical to endogenous hormone.
What are synthetic progestins?
Progestins are laboratory-made compounds designed to mimic progesterone’s effects — specifically its ability to protect the uterine lining from estrogen-driven overgrowth. They were developed because pharmaceutical companies cannot patent a molecule identical to one the body makes, creating a commercial incentive to tweak the structure.
The result is a family of compounds — medroxyprogesterone acetate (MPA, sold as Provera), norethindrone, levonorgestrel, drospirenone, and others — that activate progesterone receptors but also interact with other steroid receptors (androgenic, glucocorticoid, mineralocorticoid) to varying degrees. That cross-reactivity is the root of much of the controversy.
MPA became the most widely used progestin in hormone replacement therapy (HRT), largely because it was the synthetic chosen in the landmark Women’s Health Initiative (WHI) study published in 2002. The study linked combination HRT (conjugated equine estrogens + MPA) to increased rates of breast cancer and cardiovascular events — findings that sent HRT prescriptions into freefall and left a generation of women undertreated for menopausal symptoms.
A key problem with the WHI conclusions: the study used synthetic MPA, not bioidentical progesterone. Critics and researchers have argued for two decades that the two should not be conflated — and the evidence increasingly supports that view.
How they differ at the cellular level
The most striking differences show up in breast tissue and the cardiovascular and nervous systems.
Breast tissue
Estrogen promotes the proliferation of breast cells. Natural progesterone appears to counteract this by shortening estrogen receptor signalling time, increasing the proportion of “safer” estrogen beta receptors, and triggering genes that slow cell division. Several in vitro studies have shown that adding natural progesterone to breast cell cultures exposed to estrogen does not increase — and may even reduce — proliferative activity.
MPA behaves differently. Research published in Breast Cancer Research and Treatment and other journals has shown that MPA can actually amplify estrogen’s growth-promoting effects on breast tissue, partly through its androgenic activity and partly because it activates progesterone receptor B without the balancing effect of receptor A. It also appears to blunt the natural protective role that testosterone plays at the breast.
Cardiovascular system
The French Cohort study (E3N), which followed over 80,000 women, found that postmenopausal women using estrogen combined with natural progesterone had no increased risk of breast cancer compared with those using no hormones. Women using estrogen with synthetic progestins, particularly MPA and norethindrone, did show elevated risk. A 2019 analysis in PLOS Medicine with over 100,000 women confirmed the pattern: oral MPA was associated with higher breast cancer risk than micronised (bioidentical) progesterone.
On arterial health, natural progesterone has been shown in studies to have a vasodilatory effect — helping blood vessels relax — while MPA has been associated with vasoconstriction and may counteract the beneficial cardiovascular effects of estrogen on arterial flexibility.
The brain
This is perhaps where the distinction is most striking. Progesterone and its metabolite allopregnanolone (ALLO) are potent neurosteroids. They act on GABA-A receptors (the brain’s primary calming receptors), support myelin repair, reduce neuroinflammation, and have been implicated in protecting against Alzheimer’s disease. Following traumatic brain injury, progesterone has been studied as a neuroprotective agent — it’s considered safe enough that the FDA has approved emergency IV administration without patient consent in trauma settings.
Synthetic progestins — particularly MPA — do not replicate these benefits. MPA does not convert to allopregnanolone, and some studies suggest it may even interfere with the neuroprotective effects of estrogen, rather than complementing them.
Side-by-side comparison
| Property | Bioidentical progesterone | Synthetic progestins (e.g. MPA) |
|---|---|---|
| Molecular structure | Identical to endogenous hormone | Modified — not identical to human progesterone |
| Breast cell proliferation | Does not increase; may reduce | May increase, especially with estrogen |
| Cardiovascular effects | Vasodilatory, neutral to beneficial | May counteract estrogen’s vascular benefits |
| Brain / neuroprotection | Converts to allopregnanolone; neuroprotective | Does not convert; may blunt estrogen’s brain benefits |
| Receptor selectivity | Primarily PR-A and PR-B | Cross-reacts with androgen, glucocorticoid receptors |
| Metabolic effects | Mild — slight sleepiness, can aid sleep | Variable — may worsen lipids, mood, and insulin sensitivity |
| FDA approval for HRT | Yes (Prometrium, oral micronised) | Yes (MPA/Provera and others) |
Forms of bioidentical progesterone
The most studied and widely prescribed form is oral micronised progesterone (OMP), sold as Prometrium in North America and Utrogestan in Europe. “Micronised” means the particle size has been reduced to improve absorption, since progesterone on its own is poorly absorbed. It is typically taken at night because it can cause mild drowsiness — a side effect many women find welcome.
Topical progesterone cream is available over the counter in low doses (since the FDA considers progesterone safe enough for non-prescription sales). However, skin absorption is variable and transdermal progesterone generally does not achieve serum levels sufficient to protect the uterine lining in women using systemic estrogen therapy — something important to understand if you’re postmenopausal and using both.
Vaginal progesterone suppositories and gels are commonly used in fertility treatments and have also gained ground in menopause management, particularly when the systemic effects of oral progesterone are not desired.
Current clinical guidance
Reflecting the accumulating evidence, several major medical bodies have updated their thinking. The Menopause Society (formerly NAMS) and the British Menopause Society now acknowledge that natural progesterone carries a more favourable safety profile than older synthetic progestins — particularly regarding breast cancer risk — while still emphasising that the data is not complete and all HRT decisions should be individualised.
The British guidelines in particular have moved toward recommending micronised progesterone as the preferred progestogen component of HRT for most women, describing it as having “a more favourable effect on breast cancer risk, cardiovascular risk and metabolic parameters compared with synthetic progestins.”
A note on the WHI and context
The WHI’s findings — while important — are increasingly understood to reflect the specific combination used (conjugated equine estrogens + MPA), the age group studied (most women were 10+ years postmenopause), and the oral route of estrogen administration. Younger, recently menopausal women starting body-identical hormones face a substantially different risk picture. The “timing hypothesis” suggests the window for hormone therapy matters greatly.
What this means if you’re navigating HRT decisions
If you are perimenopausal or postmenopausal and considering hormone replacement therapy, the conversation with your clinician should include not just whether to use a progestogen, but which one. Asking specifically about micronised progesterone — rather than accepting whatever progestin is in a given combined pill or patch — is a reasonable, evidence-supported request.
If you have a uterus, you need a progestogen alongside estrogen to protect the uterine lining. There is no getting around this. But the choice of progestogen is not arbitrary, and the evidence increasingly suggests bioidentical progesterone offers real advantages — particularly for breast health and neurological wellbeing.
As with all hormone decisions, route, dose, timing, and individual health history matter. Working with a clinician who is up to date on the evolving literature — and who treats the WHI as historical context rather than gospel — makes a significant difference.
Fournier A et al. “Unequal risks for breast cancer associated with different hormone replacement therapies.” Breast Cancer Research, 2008.
Campagnoli C et al. “Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.” Journal of Steroid Biochemistry and Molecular Biology, 2005.
Asi N et al. “Progesterone vs. synthetic progestins and the risk of breast cancer.” Systematic Reviews, 2016.
British Menopause Society. Recommendations on HRT. Updated 2023.
Menopause Society (NAMS). 2023 Menopause Hormone Therapy Position Statement.
Prior JC. “Progesterone for Symptomatic Perimenopause Treatment.” Journal of Midwifery and Women’s Health, 2011.
Wright DW et al. “ProTECT: A Randomized Clinical Trial of Progesterone for Acute Traumatic Brain Injury.” Annals of Emergency Medicine, 2007.
This post is for educational purposes. It does not constitute medical advice. Always discuss hormone therapy decisions with a qualified healthcare provider.